Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy Abstract #994

Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Aim(s): To evaluate the influence of biomarker expression on the response rate (RR) and overall survival (OS) in patients with inoperable grade 2 (G2) and G3 EPNET who received chemotherapy.
Materials and methods: Retrospective analysis of pts with G2/G3 EPNET treated with platinum-based chemotherapy. Clinical and laboratorial data were collected from an electronic database. Pts had their paraffin-embedded tumor tissues tested for ERCC1, BCL2, timidilate synthase (TS) and Lin28 by immunohistochemistry (IHC). Expression score was based on the intensity of staining (graded as 0-3).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result